Key result
KCNC2 pathogenic variants in 18 epilepsy patients showed gain of function in 3 severe cases and loss of function in 1 milder case, with 8 patients achieving seizure freedom on valproic acid.
Observational (n=18)
KCNC2 pathogenic variants are associated with a spectrum of epilepsy phenotypes driven by both gain- and loss-of-function mechanisms, with some patients showing a strong response to valproic acid.
Answers are grounded in this paper and cite their sources.
KCNC2 variants may guide epilepsy phenotyping and valproic acid trials; hypothesis-generating and requires prospective validation.
BACKGROUND AND OBJECTIVES: encodes Kv3.2, a member of the Shaw-related (Kv3) voltage-gated potassium channel subfamily, which is important for sustained high-frequency firing and optimized energy efficiency of action potentials in the brain. The objective of this study was to analyze the clinical phenotype, genetic background, and biophysical function of disease-associated Kv3.2 variants. METHODS: oocytes. RESULTS: variants in 18 patients with various forms of epilepsy, including genetic generalized epilepsy (GGE), developmental and epileptic encephalopathy (DEE) including early-onset absence epilepsy, focal epilepsy, and myoclonic-atonic epilepsy. Of the 18 variants, 10 were de novo and 8 were classified as modifying variants. Eight drug-responsive patients became seizure-free using valproic acid as monotherapy or in combination, including severe DEE cases. Functional analysis of 4 variants demonstrated gain of function in 3 severely affected DEE cases and loss of function in 1 case with a milder phenotype (GGE) as the underlying pathomechanisms. DISCUSSION: 3.2 in the regulation of brain excitability.
No takes yet. Share an insight, caveat, or question.
Schwarz et al. (2022) conducted an observational in Epilepsy with KCNC2 pathogenic variants (n=18). KCNC2 pathogenic variants was evaluated on Clinical phenotype, genetic background, and biophysical function. KCNC2 pathogenic variants in 18 epilepsy patients showed gain of function in 3 severe cases and loss of function in 1 milder case, with 8 patients achieving seizure freedom on valproic acid.
Synapse has enriched 10 related papers. Consider them for comparative context: